Composition for suppressing drug resistance of anticancer drug in prostate cancer

By inhibiting ST3GAL2 to suppress SSEA-4 expression, the composition addresses drug resistance in mCRPC, enhancing the efficacy of anticancer drugs in AR-negative prostate cancer cells.

JP2024169357APending Publication Date: 2024-12-05UNIVERSITY OF THE RYUKYUS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024082365
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-21
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The mechanism of drug resistance in metastatic castration-resistant prostate cancer (mCRPC) is not fully understood, particularly in AR-negative cancer cells, leading to ineffective hormone therapy and long-term survival challenges.

Method used

A composition that suppresses the expression or function of the sialyltransferase ST3GAL2, which is involved in SSEA-4 synthesis, using compounds like siRNA, miRNA, shRNA, antibodies, or low-molecular weight compounds to inhibit SSEA-4 expression, thereby overcoming drug resistance.

Benefits of technology

The composition effectively reduces drug resistance in prostate cancer cells, particularly AR-negative cells, enhancing sensitivity to anticancer drugs such as docetaxel and cabazitaxel, and providing a mechanism to manage drug resistance in mCRPC.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169357000001_ABST
    Figure 2024169357000001_ABST
Patent Text Reader

Abstract

To elucidate the mechanism of drug resistance in mCRPC and provide a technique for overcoming the drug resistance.SOLUTION: A composition according to the present invention contains a compound that suppresses expression of or inhibits a function of ST3GAL2 as an active ingredient, and aims at suppressing anticancer drug resistance in prostate cancer. Specifically, the active ingredient in the composition according to the present invention directly suppresses the protein expression of ST3GAL2, or inhibits the enzymatic function of ST3GAL2, thereby exhibiting effect on suppressing anticancer drug resistance in prostate cancer.SELECTED DRAWING: Figure 8
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for suppressing drug resistance to anticancer drugs in prostate cancer. [Background technology]

[0002] Among cancers, prostate cancer is the leading cause of cancer incidence each year among American men, with the number of cases predicted to be 268,490 in 2022. Prostate cancer has also been the first or second most common cause of cancer incidence among Japanese men in recent years, ranking first with 94,784 cases in 2019. In addition, the number of deaths from prostate cancer is second only to lung cancer among American men, and fifth among Japanese men. From the standpoint of the number of patients and deaths, therefore, efforts to combat prostate cancer are extremely important.

[0003] Meanwhile, in cancer in general, including prostate cancer, solving drug resistance can be said to be an urgent unmet medical need. Metastatic castration-resistant prostate cancer (mCRPC) is known as a type of prostate cancer that exhibits this type of drug resistance.

[0004] In metastatic prostate cancer, the majority of cancer cells at the time of initial diagnosis are androgen receptor (AR) positive. Therefore, metastatic prostate cancer is sensitive to hormone therapy (androgen deprivation therapy and AR-targeting drugs) that act on AR signaling, and is called metastatic castration / hormone-sensitive prostate cancer (mCSPC or mHSPC). In addition to androgen deprivation therapy, which is the basic treatment for mCSPC, AR-targeted drugs and the anticancer drug docetaxel are now covered by insurance. Until recently, treatments centered on androgen deprivation therapy for mCSPC before the combination of AR-targeted drugs and the anticancer drug docetaxel became ineffective against hormone therapy within two years, and most patients progressed to metastatic castration-resistant prostate cancer (mCRPC).

[0005] When mCRPC progresses, not only AR-positive cancer cells but also AR-negative cancer cells, for which hormone therapy is ineffective, proliferate. Loss of AR is observed in up to 20% of mCRPC cases, and the disease progresses with low PSA levels (low PSA progression). Prostate-specific antigen (PSA) is used to monitor prostate cancer progression, but because PSA production is mediated by the transcription factor AR, PSA cannot detect the proliferation of AR-negative cancer cells. Therefore, in mCRPC, regular imaging tests are required in addition to PSA measurements to detect AR-positive cancer cells. Furthermore, because AR-negative cancer cells are more malignant than AR-positive cancer cells, it is important to understand the proliferation status of AR-negative cancer cells and select appropriate therapeutic agents for mCRPC. In the final stage of mCRPC treatment, AR-targeted drugs become ineffective and anticancer drugs are used. Although anticancer drugs are effective at first, acquired resistance gradually develops and they become ineffective, so long-term survival cannot be expected.

[0006] In recent years, it has become clear that stage-specific embryonic antigen-4 (SSEA-4), an embryonic stem cell marker, is highly expressed in AR-negative cancer cells for which hormone therapy is ineffective. It has also been reported that SSEA-4 is involved in chemotherapy resistance in breast cancer (Non-Patent Document 1). [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Aloia A, et al. The sialyl-glycolipid stage-specific embryonic antigen-4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features. Breast Cancer Res 2015; 17: 146. DOI: 10.1186 / s13058-015-0652-6. [Non-Patent Document 2] Zhang W, et al. mTORC1 maintains the tumorigenicity of SSEA-4+ high-grade osteosarcoma. Sci Rep 2015; 5: 9604. DOI: 10.1038 / srep09604 Summary of the Invention [Problem to be solved by the invention]

[0008] The mechanism by which drug resistance is acquired in mCRPC has yet to be fully elucidated. Given these circumstances, the inventors began research to clarify the mechanism by which mCRPC acquires drug resistance, focusing on SSEA-4 and the sialyltransferase ST3GAL2 (Figure 1), which is involved in the synthesis of SSEA-4.

[0009] Against the background of the above circumstances, the objective of the present invention is to clarify the mechanism of drug resistance in mCRPC and to provide a technique for overcoming drug resistance. [Means for solving the problem]

[0010] After extensive research, the inventors discovered that when they knocked out the gene for ST3GAL2, a sialyltransferase involved in the synthesis of SSEA-4 in an AR-negative prostate cancer cell line, the KO clones showed reduced resistance to two types of anticancer drugs, thus completing the invention.

[0011] The present invention comprises the following configuration. [1] A composition for suppressing drug resistance to anticancer drugs in prostate cancer, comprising a compound that suppresses the expression or inhibits the function of ST3GAL2. [2] The composition according to [1], wherein the compound is an RNAi-type drug (siRNA, miRNA, shRNA) against ST3GAL2. [3] The composition according to [1], wherein the compound is an antibody, an antibody fragment, or a low molecular weight compound. [4] The composition described in [1], wherein the prostate cancer is either metastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer. [5] The composition described in [1], wherein the anticancer drug is either docetaxel or cabazitaxel. [6] A composition described in any of [1] to [3], wherein the anticancer drug is either docetaxel or cabazitaxel, and the compound is combined with either docetaxel or cabazitaxel. Effect of the Invention

[0012] The present invention has clarified part of the mechanism of drug resistance in mCRPC and made it possible to provide a technique for overcoming drug resistance. [Brief description of the drawings]

[0013] [Figure 1] Diagram explaining the mechanism of action of ST3GAL2. [Diagram 2]The figure shows the results of examining the expression of SSEA-4 in parent cells (DU145) and ST3GAL2 gene knockout clones. A shows the results of immunostaining of glycolipids extracted from each cell line using anti-SSEA-4 monoclonal antibody. B shows the results of orcinol staining of the extracted glycolipids. [Diagram 3] FIG. 1 shows the results of an analysis of the number of up- or down-regulated genes in complete knockout clones of the ST3GAL2 gene. [Figure 4] A diagram showing the results of gene set analysis in a complete knockout clone of the ST3GAL2 gene. [Diagram 5] This figure shows the results of investigating the cell proliferation rate of each cell line (parent DU145 cell line and knockout clone). [Figure 6] This figure shows the results of investigating MUC1 expression in each cell line (parent DU145 cell line and knockout clones). [Figure 7] The figure shows the results of investigating changes in phosphorylation of signaling molecules in each cell line (parent DU145 cell line and knockout clones). [Figure 8] The figure shows the results of investigating the effects of doxorubicin and cabazitaxel on the survival rate of each cell line (parent DU145 cell line and knockout clone). [Figure 9] The figure shows the results of investigating the effects of gemcitabine and cisplatin on the survival rate of each cell line (parent DU145 cell line and knockout clone). [Figure 10] This figure shows the results of investigating the effect of doxorubicin on the survival rate of each cell line (parent DU145 cell line, and knockout clones). [Figure 11] FIG. 1 shows the results of examining changes in ST3GAL2 mRNA expression in DU145 cell lines in the presence of docetaxel or cabazitaxel. [Figure 12] This is a graph showing the changes in gene expression related to drug resistance, etc. obtained by RNA-seq in Table 1-3, as shown by RT-PCR. [Figure 13] A schematic diagram showing how ST3GAL2 is positioned at the top and controls the expression of various molecules involved in cancer progression. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The composition of the present invention will now be described.

[0015] The composition of the present invention contains as an active ingredient a compound that suppresses the expression or inhibits the function of ST3GAL2, and is intended to suppress drug resistance to anticancer drugs in prostate cancer. That is, the active ingredient in the composition of the present invention suppresses the expression of ST3GAL2 protein itself or inhibits the enzyme function of ST3GAL2, thereby exerting an effect of suppressing anticancer drug resistance in prostate cancer.

[0016] In the present invention, the prostate cancer does not need to be particularly limited as long as it is a prostate cancer that can induce drug resistance due to ST3GAL2, but the composition of the present invention can be preferably used for AR-negative prostate cancer or metastatic castration-resistant prostate cancer.

[0017] The active ingredient in the present invention may be a compound that suppresses the expression or inhibits the function of ST3GAL2. The active ingredient used in the present invention is not particularly limited as long as it can suppress the expression or inhibit the function of ST3GAL2, and various compounds can be used. Examples of compounds that suppress the expression of ST3GAL2 include siRNA, miRNA, shRNA, etc. In addition, these RNAi-type compounds can be used as active ingredients in the form of DDS-based RNAi-type compounds that are made easier to reach the target site using cyclodextrin, liposomes, etc. Examples of compounds that inhibit the function of ST3GAL2 include antibodies, antibody fragments, low molecular weight compounds, etc. In addition, these antibodies, etc. can be made into liposomes, nanoparticles, polymer complexes, etc., and the antibodies, etc. with adjusted pharmacokinetics can be used as active ingredients.

[0018] The composition of the present invention can be used to suppress drug resistance in prostate cancer, and preferably, either docetaxel or cabazitaxel can be selected as the anticancer drug. The composition of the present invention may be used as a combination composition further containing docetaxel or cabazitaxel as an active ingredient. That is, the composition can be configured as a composition (combination drug) that exhibits an anticancer effect against prostate cancer while suppressing drug resistance.

[0019] The composition of the present invention may contain various pharma- ceutically acceptable additives, such as stabilizers, excipients, binders, diluents, pH adjusters, isotonicity agents, coating agents, solubilizers, dissolution aids, lubricants, gelling agents, etc.

[0020] The composition of the present invention can be administered in various forms, including oral administration (powders, granules, tablets, capsules, syrups, etc.), injections (solutions, emulsions, suspensions, etc.), transdermal agents (patches, creams, gels, etc.), etc. EXAMPLES

[0021] <<Experimental Example 1, Knockout of the ST3GAL2 gene using CRISPR / Cas9>> Experiments were carried out to establish ST3GAL2 gene knockout prostate cancer cell lines.

[0022] 1. Using CRISPR-Cas9 gene editing technology, we knocked out the ST3GAL2 gene in DU145 cells, an AR-negative prostate cancer cell line. 2. DU145 cells were co-transfected with the gRNA vector and a GFP expression vector containing a puromycin functional cassette. After treatment with puromycin, resistant cell colonies were isolated to establish stable cell lines. All of these clones were confirmed by PCR and Sanger sequencing to have correct chromosomal integration of GFP-Puro DNA into the ST3GAL2 gene site via the homologous recombination site (not shown).

[0023] 3. We also analyzed the target site mutations in the other alleles of these clones by Sanger sequencing of the PCR products. Two partial knockout clones (clones 2 and 5) had one wild-type allele and one ST3GAL2 gene c.1173del mutation, while the other complete knockout clone only had the c.1231_1234del mutation allele (not shown).

[0024] 4. To confirm whether the knockout cell lines had lost sialyltransferase activity, the expression of SSEA-4 was analyzed by high performance thin layer chromatography (HPTLC) immunoblotting. (1) Glycolipids were extracted from each cell and separated by thin-layer chromatography. (2) After reacting the TLC plate with anti-SSEA-4 mAb RM1, SSEA-4 was detected using the avidin-biotin system with Clarity Western ECL Substrate (Bio-Rad Laboratories, Inc., Hercules, CA). (3) SSEA-4 expression was not detected in complete knockout clones, including clones 83 and 13 (Figure 2A). (4) The two partial knockout clones (clones 2 and 5) showed lower expression levels than the parental cells, DU145 (Figure 2A). (5) Furthermore, the orcinol staining results in (B) showed that glycolipids were properly extracted from each cell, and that a band with the same mobility as SSEA-4 (a glycolipid other than SSEA-4) was confirmed in each knockout clone. (6) These results confirmed that each knockout clone had lost all or part of its sialyltransferase activity. 5. In subsequent experiments, clones 13 and 83 were used as complete knockout clones, and clones 2 and 5 were used as partial knockout clones.

[0025] <<Experimental Example 2, Changes in gene expression in ST3GAL2 gene knockout clones>> For the ST3GAL2 gene knockout clone obtained in Experimental Example 1, an experiment was carried out to examine genetic changes.

[0026] 1. To characterize and compare the transcriptional signatures associated with ST3GAL2 gene knockout, whole-exome sequencing analysis was performed in the two knockout clones compared to control cells (parental DU145 cells). 2. Compared with DU145 cells, the numbers of down-regulated genes in knockout clones 13 and 83 were 171 and 236, respectively, and the numbers of up-regulated genes were 80 and 179, respectively (Fold change |Fc|>=2 and raw p-value<0.05) (Figure 3).

[0027] 3. The results of gene analysis of the two knockout clones compared with the control are shown in Figure 4. (1) The expression of various genes involved in signal transduction pathways was found to be associated with ST3GAL2. (2) In addition, 30 drug resistance-related genes (multiple anticancer drugs, cancer immunotherapy drugs, hormone preparations, cyclin-dependent kinase inhibitors, tyrosine kinase inhibitors, etc.) were down-regulated, and 5 drug resistance-related genes (anticancer drugs) were up-regulated. Meanwhile, 7 drug sensitivity-related genes were down-regulated (Tables 1-3).

[0028] [Table 1]

[0029] [Table 2]

[0030] [Table 3]

[0031] <<Experimental Example 3, Relationship between ST3GAL2 gene knockout and cell proliferation>> We carried out experiments to examine how ST3GAL2 knockout affects cell proliferation.

[0032] 1. Cell viability was assessed using a WST-8-based assay. The knockout clones tended to show higher proliferation rates than DU145 up to 72 hours after the start of cell culture (p=0.0561) (Figures 5A and B).

[0033] 2. The results of examining MUC1 expression in each cell line are shown in Figure 6. It was found that MUC1 expression was significantly reduced by ST3GAL2 gene knockout. 3. Furthermore, we investigated the changes in several signaling molecules involved in cell proliferation. The results are shown in Figure 7. (1) Phosphorylation of PTEN and PDK1 was not affected by ST3GAL2 gene knockout, whereas serine 473 phosphorylation of AKT was significantly reduced in three of seven knockout clones and slightly suppressed in three (Figure 7A). (2) On the other hand, phosphorylation of ERK1 / 2 (p44 / 42) was increased by ST3GAL2 gene knockout, but phosphorylation of cRaf was not increased (Figure 7B). (3) The phosphorylation of upstream molecules did not change, suggesting that ST3GAL2 may be directly involved in the activation of signal transduction molecules via products such as SSEA-4. 4. Taken together, these results suggest that ST3GAL2 induces a low equilibrium in cell proliferation by up- and down-regulating various molecules involved in proliferation in multiple directions.

[0034] <<Experimental Example 4, Relationship between ST3GAL2 and Cancer Drug Resistance>> We conducted an experiment to investigate how knockout of the ST3GAL2 gene affects anticancer drug resistance.

[0035] 1. The effect of the compound on cell viability was examined using a colony formation assay. 2. Figure 8 shows the results using docetaxel and cabazitaxel. (1) The three ST3GAL2 gene knockout clones were confirmed to have significantly lower colony formation efficiency than DU145 cells with 0.25 nM docetaxel (p<0.05: Figures 8A and B). (2) Similarly, at low concentrations of 0.05 to 0.1 nM cabazitaxel (p<0.005: Figures 8C and D), the colony formation efficiency was significantly lower than that of DU145 cells.

[0036] 3. Figure 9 shows the results using gemcitabine and cisplatin. (1) It has been reported that resistance to gemcitabine is associated with increased MUC1 expression in pancreatic cancer. However, a study using gemcitabine showed a significant decrease in the colony formation rate of parental DU145 cells at 2.5 nM and 5 nM. (2) It has been reported that the drug resistance of esophageal cancer is related to the increase in MUC1 expression. However, in a study using cisplatin, a significant decrease in the colony formation rate of the parental DU145 cells was confirmed at 0.5 mM and 1 mM. Since MUC1 is controlled by ST3GAL2 (MUC1 expression was dramatically decreased in ST3GAL2 knockout clones), it was predicted that ST3GAL2 gene knockout would increase sensitivity (decreased resistance) to gemcitabine and cisplatin, but the results were contrary to expectations.

[0037] 4. Figure 10 shows the results using doxorubicin. It has been reported that doxorubicin resistance is associated with increased SSEA-4 expression in breast cancer. However, in studies using doxorubicin, no significant decrease in colony formation rate was observed at any of the concentrations tested.

[0038] 5. Regarding the relationship between ST3GAL2 and drug resistance, in the ST3GAL2 gene knockout clone, the expression of 30 genes known to be involved in drug resistance was decreased, while the expression of 4 genes was increased (Table 1, Table 2). As an example of decreased expression of these molecules, the downregulation (decreased expression) of DHX and H19 mRNA in the ST3GAL2 gene knockout clone is shown in Figure 10K. 6. On the other hand, in the ST3GAL2 gene knockout clone, seven genes related to drug sensitivity were down-regulated (Table 3). The molecule directly involved in taxane resistance has not yet been identified.

[0039] 7. Because ST3GAL2 gene knockout attenuated taxane resistance, we investigated the possibility that ST3GAL2 mRNA expression may be elevated in taxane-resistant cell lines. DU145 cell lines were cultured for a long period (docetaxel 157 PDL, cabazitaxel 131 PDL) in medium containing a relatively high concentration of 3 nM docetaxel or cabazitaxel, but no change in ST3GAL2 mRNA expression was observed compared to DU145 cell lines cultured for a short period (50 PDL) or a long period (208 PDL) in medium without taxane (Figure 11). This suggests that taxane resistance is not a function of the quantity of ST3GAL2, but rather that the presence of ST3GAL2 itself is important. Note: "PDL" is an abbreviation for "population doubling level."

[0040] 8. Changes in gene expression and phosphorylation related to drug resistance involving ST3GAL2 are related to cancer progression, including lineage plasticity, immune evasion, epithelial-mesenchymal transition (EMT), invasion, and metastasis, as well as drug resistance. Figure 12 shows an example of RT-PCR showing gene expression changes related to drug resistance obtained by RNA-seq in Table 1-3. Figure 13 shows a conceptual diagram showing that ST3GAL2 is at a higher level and controls the expression of various molecules related to cancer progression.

[0041] <<Summary>> 1. We succeeded in creating cells in which the ST3GAL2 gene was knocked out in AR-negative prostate cancer cells. 2. ST3GAL2 gene knockout clones did not have resistance to docetaxel or cabazitaxel, and showed a significantly decreased survival rate against these anticancer drugs compared with the parental cells. 3. On the other hand, no significant difference was observed between the survival rates of ST3GAL2 gene knockout clones and parental cells in the case of doxorubicin. In other words, although Non-Patent Document 1 reported that SSEA-4 is involved in drug resistance to doxorubicin in breast cancer, this study did not provide clear results indicating that SSEA-4 is involved in drug resistance to doxorubicin in AR-negative prostate cancer cells.

Claims

1. The compound consists of a compound that suppresses the expression or function of ST3GAL2. A composition that suppresses drug resistance to anticancer drugs in prostate cancer.

2. The compound is RNAi drugs (siRNA, miRNA, shRNA) targeting ST3GAL2. The composition of claim 1 .

3. The compound is It is either an antibody, an antibody fragment, or a small molecule compound. The composition of claim 1 .

4. The prostate cancer is Patients with either metastatic castration-resistant or metastatic castration-sensitive prostate cancer The composition of claim 1 .

5. The anticancer drug is Either docetaxel or cabazitaxel The composition of claim 1 .

6. The anticancer drug is In the case of docetaxel or cabazitaxel, The compound, Combination of docetaxel or cabazitaxel A composition according to any one of claims 1 to 3.